These changes promote a reduction in intravascular volume, arterial blood pressure, cardiac preload, and cardiac afterload.2,24 Among subjects with the triad of type 2 diabetes, chronic kidney disease, and no known preexisting ASCVD, those who had the highest glucosuria while treated with the SGLT2 inhibitor canagliflozin, also had the strongest protection against multiple cardiorenal outcomes.22 Here, SLC5A2 is linked to chronic kidney disease.